{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:50:11Z","timestamp":1772250611011,"version":"3.50.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review evaluates the safety profile of CAR T-cell therapy, focusing on cytopenia, hemophagocytic lymphohistiocytosis (HLH)\/macrophage activation syndrome (MAS), and other potential complications. Cytopenia, characterized by reduced blood cell counts, affects a significant proportion of patients, with rates of anemia, neutropenia, and thrombocytopenia reaching up to 60%, 70%, and 80%, respectively. Risk factors include high tumor burden, prior chemotherapy, and bone marrow involvement. Cytokine release syndrome (CRS) occurs in 13% to 77% of patients and is linked to the cytokine storm induced by CAR T cells, target antigen expression, and preexisting immune dysregulation. Other notable adverse events discussed are cytokine release syndrome, neurotoxicity, and infections. Understanding the mechanisms, risk factors, and management strategies for these adverse events is crucial for optimizing patient outcomes and unlocking the full potential of this revolutionary therapy. The review highlights the need for continued research, interdisciplinary collaboration, and evidence-based approaches to enhance the safety and efficacy of CAR T-cell therapy.<\/jats:p>","DOI":"10.1097\/coc.0000000000001124","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T09:00:25Z","timestamp":1719046825000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Optimization Strategies in CAR T-cell Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"Zaheer","family":"Qureshi","sequence":"first","affiliation":[{"name":"Department of Medicine, The Frank H. Netter MD School of Medicine at Quinnipiac University, Bridgeport, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Icahn School of Medicine at Mount Sinai\/BronxCare Health System, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur","family":"Jamil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samaritan Medical Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimsha","family":"Siddique","sequence":"additional","affiliation":[{"name":"Independent Research Associate, Watertown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/jcm8020207","article-title":"Chimeric antigen receptor T-cells: the future is now","volume":"8","author":"Mchayleh","year":"2019","journal-title":"J Clin Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"e03779","DOI":"10.1016\/j.heliyon.2020.e03779","article-title":"CAR T cell therapy: newer approaches to counter resistance and cost","volume":"6","author":"Yadav","year":"2020","journal-title":"Heliyon"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R16-20250527","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"215920","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post-CAR T cell therapy: etiology, potential mechanisms, and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"579075","DOI":"10.3389\/fonc.2020.579075","article-title":"Prevalence of cytopenia in the general population\u2014a National Health and Nutrition Examination Survey analysis","volume":"10","author":"Alpert","year":"2020","journal-title":"Front Oncol"},{"key":"R19-20250527","first-page":"204993612110367","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1080\/07853890.2022.2136748","article-title":"Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors","volume":"54","author":"Xia","year":"2022","journal-title":"Ann Med"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"997589","DOI":"10.3389\/fimmu.2022.997589","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"702644","DOI":"10.3389\/fonc.2021.702644","article-title":"New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)\u2013an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250527","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"165.e1","DOI":"10.1016\/j.jtct.2022.12.020","article-title":"Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy","volume":"29","author":"Read","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"569117","DOI":"10.3389\/fimmu.2020.569117","article-title":"Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments","volume":"11","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy\u2013associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00296-020-04636-y","article-title":"Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic","volume":"41","author":"Soy","year":"2021","journal-title":"Rheumatol Int"},{"key":"R37-20250527","first-page":"e33175","article-title":"The role of immune mechanisms, inflammatory pathways, and macrophage activation syndrome in the pathogenesis of hemophagocytic lymphohistiocytosis","volume":"14","author":"Bseiso","year":"2022","journal-title":"Cureus"},{"key":"R39-20250527","first-page":"29","article-title":"Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society","volume":"18","author":"Henter","year":"1991","journal-title":"Semin Oncol"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10067-013-2227-1","article-title":"Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review","volume":"32","author":"Vilaiyuk","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"issue":"suppl 3","key":"R43-20250527","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J Clin Med"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"1019115","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR-T cell therapy for hematological malignancies: limitations and optimization strategies","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"R48-20250527","first-page":"e13552","article-title":"The role of chimeric antigen receptor-T cell therapy in the treatment of hematological malignancies: advantages, trials, and tribulations, and the road ahead","volume":"25","author":"Rohit Reddy","year":"2021","journal-title":"Cureus"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"R50-20250527","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"152043","DOI":"10.1016\/j.semarthrit.2022.152043","article-title":"Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases-associated macrophage activation syndrome, a single center real-world analysis","volume":"55","author":"Chen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"950923","DOI":"10.3389\/fphar.2022.950923","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"914959","DOI":"10.3389\/fimmu.2022.914959","article-title":"Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R\/R acute lymphoblastic leukemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?","volume":"14","author":"Velasco","year":"2023","journal-title":"Front Neurol"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"1206983","DOI":"10.3389\/fonc.2023.1206983","article-title":"CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap","volume":"13","author":"Gatto","year":"2023","journal-title":"Front Oncol"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/JBM.S281247","article-title":"They are assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma","volume":"12","author":"Castaneda-Puglianini","year":"2021","journal-title":"J Blood Med"},{"key":"R65-20250527","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"R67-20250527","first-page":"19","article-title":"Update on the prevention and treatment of tumor lysis syndrome","volume":"3","author":"Sury","year":"2019","journal-title":"J Onconephrol"},{"key":"R68-20250527","doi-asserted-by":"crossref","first-page":"1125357","DOI":"10.3389\/fimmu.2023.1125357","article-title":"Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R70-20250527","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"R71-20250527","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2004-03-1115","article-title":"Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure","volume":"104","author":"Chen","year":"2004","journal-title":"Blood"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm\u2014definition, causes, and implications","volume":"23","author":"Jarczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"153712","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"key":"R74-20250527","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:02:57Z","timestamp":1748376177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001124"}},"subtitle":["A Comprehensive Evaluation of Cytopenia, HLH\/MAS, and Other Adverse Events"],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001124","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}